Puquitinib

Drug Profile

Puquitinib

Alternative Names: Puquitinib mesylate

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Zhejiang Medicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 06 Apr 2011 Pharmacodynamics data from a preclinical trial in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)
  • 06 Apr 2011 Phase-I development in Cancer is ongoing in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top